公司概述
BrightSpring Health Services, Inc. operates as a comprehensive home and community-based healthcare services platform within the United States, delivering integrated pharmacy and provider services through its clinical network. The company functions within the broader Healthcare sector, specifically categorized under the Health Information Services industry, which implies a focus on managing data and operational efficiency rather than direct drug manufacturing. This entity employs a substantial workforce of 23,500 individuals, reflecting its significant operational footprint across the nation. With a market capitalization of $8.82 billion and trailing twelve-month revenue of $12.91 billion, the company demonstrates substantial scale that positions it as a major player in the decentralized care model. These valuation and revenue figures indicate that the market assigns high value to its platform's ability to coordinate care outside of traditional hospital settings, suggesting a dominant position in the home health care ecosystem.
财务健康
The company reported total revenue of $12.91 billion over the trailing twelve months, with a net income of $106.35 million and an EBITDA of $485.33 million. The significant gap between the $12.91 billion in revenue and the $106.35 million in net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, absorb approximately 98.5% of top-line revenue before reaching the bottom line. However, the EBITDA figure of $485.33 million suggests that at an operating level excluding capital expenditures and interest, the business generates considerable cash conversion before financing costs. The free cash flow stands at -$334,849,888, indicating that current capital expenditures and working capital requirements exceed operating cash generation, which limits immediate financial flexibility for dividends or aggressive buybacks without external funding. Gross margin is 11.8%, while the operating margin is 3.0% and the profit margin is 1.5%; these figures indicate a high-cost business model typical of service-oriented healthcare, where thin margins require volume to achieve profitability. In terms of balance sheet leverage, the company holds $88.37 million in cash against $2.71 billion in debt, resulting in a debt-to-equity ratio of 143.60, which characterizes the balance sheet as highly leveraged rather than conservative. The current ratio of 1.56 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a moderate buffer for liquidity management. Return on Equity is 5.9% and Return on Assets is 3.3%, metrics that reveal that management's effectiveness in generating returns is modest relative to the capital deployed, reflecting the capital-intensive nature of the industry.
估值评估
The trailing twelve-month P/E ratio is 95.67, while the forward P/E is projected to be 23.49, implying that the market expects a dramatic compression in the P/E multiple as earnings are anticipated to grow significantly in the coming year. The price-to-book ratio stands at 4.99, indicating that the stock trades at a substantial premium over its book value, likely reflecting investor confidence in the company's intangible assets and future service contracts. The price-to-sales ratio is 0.68, and the EV/EBITDA multiple is 24.84; these alternative valuation metrics suggest that the company is valued heavily on its sales volume and earnings potential relative to enterprise value. The 52-week trading range spans from a low of $15.48 to a high of $46.69, providing a context for price volatility and historical support/resistance levels for technical analysis. The beta value is 2.05, which means the stock exhibits more than double the price volatility of the broader market, making it highly sensitive to macroeconomic shifts and sector-specific news.
Growth & Income
Revenue growth year-over-year is 29.3%, while earnings growth year-over-year is 338.3%, indicating that earnings are growing at a rate vastly faster than revenue, which implies significant margin expansion or one-time gains driving the bottom line. As the company has a dividend yield of N/A and a payout ratio of 0.0%, it does not currently distribute dividends to shareholders, meaning the firm reinvests all earnings back into operations, debt reduction, or growth initiatives rather than paying out cash to investors. The absence of a dividend program aligns with the high debt-to-equity ratio and negative free cash flow, as the company prioritizes capital preservation and expansion over income generation. The overall growth and income profile presents a high-risk, high-reward scenario characterized by explosive earnings expansion but a lack of current income yield for investors seeking regular cash distributions.